1. Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study
- Author
-
Eiko Nagata, Yasuharu Kashiwagura, Eisaku Okada, Shimako Tanaka, Shinichiro Sano, Mitsuhiro Nishida, Satoshi Hayano, Satoru Iwashima, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Kazuo Umemura, and Shinya Uchida
- Subjects
Propranolol ,Cream ,Infantile hemangioma ,Pilot study ,Infants ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Infantile hemangioma (IH) is a common tumor in infants that gradually resolves and is often untreated. However, for cosmetic reasons, parents often opt for treatment. Oral propranolol, the first-line therapy for IH, is sometimes associated with several side effects, including hypotension, bradycardia, and hypoglycemia. No clinical studies on topical propranolol have been conducted using standardized procedures. We evaluated the efficacy and safety of topical propranolol in patients with IH. This multicenter, prospective pilot study was conducted from June 2019 to October 2020 and involved eight Japanese infants aged 35–150 days with proliferating IH. Patients were treated with 5% propranolol cream twice daily. We examined the efficacy rate based on central evaluation (complete or near-complete healing of the target hemangioma) at weeks 24 and 12, respectively, compared to baseline values. The efficacy rate at week 24 was 68.8% (95% confidence interval: 44.1–85.9%). The surface area, maximum diameter, and color intensity of the target IH decreased over time. Adverse event and drug-related adverse event rates were 87.5% and 0%, respectively. Propranolol cream may be effective and safe in Japanese patients with IH and may be considered a first-choice treatment for small and superficial IHs in cosmetically problematic areas.
- Published
- 2022
- Full Text
- View/download PDF